Eye scans may spot Epilepsy's silent brain damage

NCT ID NCT07716930

ENROLLING_BY_INVITATION Knowledge-focused Sponsor: Kemal Tutkavul Source: ClinicalTrials.gov ↗

First seen Jul 21, 2026 · Last updated Jul 22, 2026 · Updated 1 time

Summary

This study investigates whether epilepsy causes progressive damage to the brain by looking at the retina—the light-sensitive layer at the back of the eye. Researchers will use optical coherence tomography (OCT) to measure retinal thickness and blood vessel changes in 250 adults aged 18–40 with epilepsy or other neurological conditions. They will also measure inflammatory markers in the blood. The goal is to see if retinal changes can help predict which patients will develop drug-resistant epilepsy and how the disease progresses over 18 months.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to
If successful, this could lead to a simple, non-invasive eye scan to track epilepsy progression and identify drug-resistant cases early.
What could go wrong
This is an observational study, not a treatment trial. It may find no clear link between retinal changes and epilepsy, or the results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EPILEPSY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Drug Resistant Epilepsy epilepsy Nerve Degeneration Neuroinflammatory Diseases

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Saglik Bilimleri University Haydarpasa Numune Education and Research Hospital Neurology Clinic

    Istanbul, 34668, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.